TYPES OF NASH
Two types of NASH exist: primary NASH (which is associated with metabolic syndrome-related conditions, such as obesity, type 2 diabetes, and hyperlipemia) and secondary NASH (which occurs after obesity-related intestinal surgery, rapid weight loss in the obese, total parenteral nutrition, treatment with drugs such as amiodarone or perhexiline maleate, lipodystrophy, or Wilson's disease) (Medina et ai, 2004) . Although many aspects of the disease are common to both presentations, this present work focuses mainly on the pathogenesis of primary NASH.
Differential diagnosis between simple steatosis and steatohepatitis is of vital importance because the former has a benign process, while the latter tends to develop into advanced fibrosis or even cirrhosis.
Conventional liver tests cannot differentiate between alcoholic and non-alcoholic hepatitis (Mathiesan et al., 1999; Lee, 1989; Itoh et al., 1982) . On physical examination, obesity is often the dominating finding.
Elevated ALT levels observed in NASH, which appear to be a consequence of steatosis, might involve balloonization necrosis, gr-glutamyl transpeptidase and alkaline phosphatase can be mildly elevated, but bilirubin, albumin and prothrombin time are usually normal unless the disease is advanced.
Immunoserologic findings compatible with autoimmune hepatitis are commonly present with primary NASH (Hay et al., 1989; Adler and Schaffner, 1997) . Diagnosis of primary NASH must include a negative evaluation for chronic hepatitis C virus infection (antibody to hepatitis C virus) and hepatitis B virus infection (hepatitis B surface antigen). Ceruloplasmin levels, a-1-anti-trypsin levels are usually normal in patients with NASH. Idiopathic genetic hemochromatosis must be excluded even in the presence of elevated levels of serum ferritin and transferin saturation. Autoimmune serology (antimitochondrial antibody, antinuclear antibody, antismooth muscle antibody, and anti-liver/kidney microsomal antibody)
should remain negative in patients with NASH, except for some patients presenting with low titre antinuclear antibody positivity (Pinto etal., 1996) .
Diagnosis of NAFLD is based on two criteria: (i) establishing the presence of a fatty liver or steatohepatitis, and (ii) establishing the nonalcoholic nature of the disease process. Radiologic imaging of the liver with sonography, computed tomography (CT) or magnetic resonance imaging (MRI) has an adequate threshold for detection of fatty infiltration of the liver, used either singly or in combination. Each of these modalities has its own pitfalls and cannot distinguish steatosis from steatohepatitis.
Liver biopsy is the gold standard for diagnosis of NAFLD/NASH for the following important reasons: (i) to confirm diagnosis and establish severity of fibrosis and presence of cirrhosis, and (ii) to exclude other coexisting conditions that can result in hepatitic steatosis. However, ethical consideration as well as inherent risk associated with this procedure limit its widespread applicability. Histological diagnosis of steatohepatitis relies on a constellation of lesions that include steatosis (mainly macrosteatosis, occasionally microsteatosis), ballooning of hepatocytes (hepatocyte injury), perisinusoidal fibrosis and a mixed lobular inflammatory infiltrate (Burt etal., 1998) . Currently, minimal histological criteria required for diagnosis are the presence of steatosis and intralobular necrotic inflammatory reactions (Lee, 1989) .
Focal necrosis is usually centrilobular (Lee, 1989) and the cellular response involves lymphocytes, mononuclear cells and neutrophils. The ultrastructure of Mallory bodies in patients with NASH is similar to that seen in patients with alcoholic hepatitis (Itoh et al., 1982) . Mallory bodies are not now considered necessary for diagnosis (Bonkovsky et al., 1999) . Diagnosis of NASH thus requires careful examination of both the clinical signs and anatomic findings.
Major associated conditions
Insulin resistance plays a fundamental role in type-2 diabetes mellitus, as well as in obesity, and is the most predisposing and reproducible factor in NASH (Belfiore and lannello, 1998) ( Table I) .
Diabetes mellitus
Up to one third of patients have diabetes or fasting hyperglycemia at the time of diagnosis with NASH (Bacon et al" 1994; James and Day, 1998) . The most frequent association is type-2 diabetes, although difficult-to-control insulin-dependent diabetes may also be present (Lenaerts etal., 1990) . Diabetes is an important independent predictor of severe hepatic fibrosis in NASH (Angulo et al., 1999) . Furthermore, glucose intolerance occurs secondarily to cirrhosis in 60-80% of these patients, 10-30% of whom eventually develop diabetes (Petrides et al., 1994) . Autopsy studies have revealed that type-2 diabetes is associated with NASH, with a 2.6-fold increased risk (Wanless and Lentz, 1990) .
Obesity
Between 39 and 100% of patients with NASH are overweight (BMI > 25 kg/m2) or obese (> 30 in Caucasians and > 27 in Asians) (James and Andersen and Gluud, 1994; Marceau et al., 1999; Naveau et al., 1997 ). An autopsy study found the prevalence of NASH to be 6-fold greater among obese versus lean individuals (Wanless and Lentz, 1990) . Liver biopsy demonstrates steatosis in more than 75% of the morbidly obese; NASH is identified in a quarter of these patients, and cirrhosis in 3-11% (Luyekx et al., 2000) . Obesity also correlates with the severity of fibrosis in NASH, regardless of the diabetes status or age (Ratziu et al., 2000) . Garci'a-Monzon et al. (2000) found that the older the age and the higher the grade of steatosis, particularly if intrahepatic inflammation is also present, the higher the risk of fibrosis. Distribution of body fat may be important; a significant correlation has been found between grade of steatosis and waist-to-hip ratio (Garcia-Monzon et al., 2000) , indicating the importance of visceral fat as a predictor of steatosis (Matsuzawa et al., 1995) . Lean males rarely present with significant hepatic fibrosis; Ratziu et al. (Ratziu et al., 2000) did not find fibrosis or cirrhosis in patients younger than 50 years with a BMI < 28 kg/m2 and normal triglyceride values.
Hyperlipemia
Between 20 and 80% of patients with NASH have hyperlipemia (James and . Although triglyceride and/or total serum cholesterol levels are increased, there is a greater association with triglyceride values, especially for hyperlipemias 2b and 4, versus 2a . A relevant role has been ascribed to hypertriglyceridemia in the pathogenesis of NASH, since a correction of this lipid anomaly has been associated with improved liver function tests (Fiatarone et at, 1991) .
Rapid weight loss
NASH has been associated with rapid weight loss following surgery for obesity, extensive intestinal resection, and severe fasting (Reid, 2001 ).
Age and sex
Older age and female sex are considered independent factors associated with liver fibrosis in NASH (Angulo etai, 1999; Reid, 2001 ).
Other Conditions associated with NASH
Jejunoileal bypass, gastroplasty, gastric bypass and other surgical techniques leading to rapid weight loss, as well as feeding disorders such as anorexia or bulimia, celiac disease, jejunal diverticulosis, other causes of bacterial overgrowth, total parenteral nutrition, abetalipoproteinemia, partial lipodystrophy, Weber-Christian disease, toxic oil syndrome, etc., are related to NASH development (Reid, 2001 ).
Drug-induced NASH
Cardiovascular drugs such as amiodarone, perhexiline maleate, and more rarely calcium channel blockers such as nifedipine and diltiazem, high-dose glucocorticoids, synthetic estrogens, tamoxifen, chloroquine, etc., may also be associated with NASH (Reid, 2001 ). Amiodarone, perhexiline maleate, diethylaminoetoxyhexestrol and tamoxifen cross the mitochondrial external membrane without difficulty because of their lipophilic properties, and are "pushed" into the mitochondria from the intermembranous space by the high electrochemical potential at the internal membrane, thus reaching high intramitochondrial levels. Beta-oxidation (causing steatosis) is thus inhibited, and electron transfer throughout the respiratory chain is blocked, which leads to a transfer of electrons to oxygen, thereby forming superoxide radical anions and generating oxygen free radicals. (Angulo, 2002) . The accumulation of toxic levels of free fatty acids increases the oxidative stress with the formation of free radicals, including hydrogen peroxide and superoxide. Abnormal lipid peroxidation ensues, resulting in direct hepatocyte injury, release of toxic by products, inflammation, and fibrosis (Andy et al., 2002) .People suffering from NASH demonstrated steatosis, hepatocyte ballooning, and intra-acinar and portal inflammation (Brunt at a!., 1999) .Chronic hepatocellular injury, necroinflammation, progressiver fibrosis, and ultimately cirrhosis may be initiated by peroxidation of hepatic lipids and injury-related cytokine release (Festi et al., 2004) . 
Two hit theory
In 1998, Day and James first proposed the two hit' hypothesis for pathogenesis of NASH. The first hit is steatosis, and this is postulated to sensitize the liver to the second hit, which may be oxidative stress or abnormal cytokine production. Oxidative stress and lipid peroxidation are candidates for the second hit in the pathogenesis of NASH.
First Hit
The presence of excess fat is a prerequisite for the subsequent events of NASH. The main characteristic of NAFLD is the accumulation of triglycerides (TG) as fat droplets within the cytoplasm of hepatocytes. It is defined practically as more than 10% of hepatocytes having fat droplets evident on liver biopsy (Neuschwander-Tetri and Caldwell, 2003) . Increased delivery of both free fatty acids (FFA) and TG to the liver, diminished hepatic utilization of FFA, diminished export of TG from the liver, and impaired betaoxidation of FFA within hepatocytes cause TG accumulation within the cytoplasm of hepatocytes (Lewis et ai, 2002, Haque and Sanyal, 2002; Browning and Horton, 2004) . Excess carbohydrates, either from dietary sources or de novo gluconeogenesis in the liver, are also a major stimulus for de novo fatty acid synthesis in the liver. Paradoxically, direct uptake of dietary fat as chylomicron remnants or FFA constitutes a relatively minor contribution to liver fat accumulation (Donnelly et ai, 2005) .
Insulin resistance is a common cause of fat accumulation in the liver. However, we also know that a small subgroup of NAFLD patients do not exhibit detectable features of impaired insulin sensitivity. This suggests that possibilities other than insulin resistance are important in a subset of patients. Furthermore, a growing body of evidence suggests that insulin resistance does not act only as a first hit, but also may play an important role in the inflammation and hepatocellular injury that characterize NASH (Figure 3 ) (Neuschwander-Tetri and Caldwell, 2003; Browning and Horton, 2004; Bugianesi etal., 2005) . 
Second hit
A liver with excess fat may be more vulnerable to stressors such as reactive oxygen species (ROS), adipokines, and cytokines than a normal liver. The regenerative capacity of a fatty liver is also impaired.
Yang and colleagues demonstrated that obese mice with fatty livers clear endotoxins less than nonobese controls (Yang et al., 1997) . Nonetheless, the factors that play key roles in the development of NASH from NAFLD remain uncertain. Some possibilities include the duration of fatty infiltration of the liver and the duration and severity of hyperinsulinemia. Other possible second hits are oxidative stress (increased ROS and decreased antioxidants), lipid peroxidation and reactive metabolites such as malondialdehyde and 4-hydroxynonenal, adipose tissue products, transforming growth factor-3,1 Fas ligand, mitochondrial dysfunction and respiratory chain deficiency, and small intestinal bacterial overgrowth (endotoxins and TNF-a) ( Figure 4 ) (Neuschwander-Tetri and Caldwell, 2003; Browning and Horton, 2004; Pessayre and Fromenty, 2005) .
Adipose tissue is now recognized as a source of important metabolic and inflammatory mediators. These adpokines have both proinflammatory (leptin, TNF-a, and IL-6) and anti-inflammatory (adiponectin) effects Crespo et at., 2001; Chitturi etal., 2002; Maeda etal., 2002; Xu et at., 2003; Hui et at., 2004) . Adiponectin also has antilipogenic effects. Adipokines regulate both hepatic and peripheral glucose and lipid metabolism. Although these cytokines and hormones normally work in a balance, this homeostasis may be disturbed in NASH patients and studies are now focusing on these changes. NASH patients have reduced adiponectin levels and increased TNF-a levels (Hui et at., 2004; Bugianesi eta/., 2005) .
Increased endotoxin levels
Morphological changes < » Apoptosis Necrosis Inflammation Fibrogenesis Figure 4 . Multiple mechanisms may play a role in causing hepatocellular injury in the setting of nonalcoholic fatty liver disease, many of which generate reactive oxygen species (ROS). For example, peroxisomal fatty acid oxidation generates hydrogen peroxide, "electron leak" from the mitochondrial respiratory chain produces superoxide, sinusoidal Kupffer cells release superoxide when stimulated by endotoxin, cytochrome P450 metabolism of fatty acids leads to electron leak from downstream redox factors to release superoxide and gut-derived ethanol may cause ROS production during its hepatocellular metabolism. Mechanisms of injury not requiring ROS may also be important and include adenosine triphosphate (ATP) depletion and disrupted organelle membranes. Hepatocytes respond with morphological changes such as ballooning, cytoskeletal protein aggregation, apoptosis, and necrosis. Individually or in sum, these processes stimulate inflammation and fibrogenesis, the latter leading to cirrhosis in some patients.
Insulin resistance and NASH
Insulin resistance plays a primary role: it is the most specific finding in NASH, and it can be observed in most patients, whether they present overweight or with type2 diabetes Pagano et ai, 2002) . This primary resistance leads to hyperinsulinemia and is associated with the metabolic syndrome (Chitturi et ai, 2002; Pagano et al., 2002; Marchesini et ai, 2001) , of which NASH is considered to represent the hepatic expression (Marchesini etal., 2003) .
Oxidative stress, lipid peroxidation and NASH
There is growing evidence implicating FFA in the production of oxidative stress within hepatocytes.
Increased fatty acid zb-oxidation as well as peroxisomal fatty acid oxidation can both lead to increase in reactive oxygen species generation and subsequent lipid peroxidation. In the fasting state, patients with NAFLD have increased plasma levels of MDH butyrate (Sanyal et al., 2001) .Under normal conditions;
hepatic aerobic metabolism involves a steady-state production of pro-oxidants such as reactive oxygen species (ROS) and reactive nitrogen species (RNS), which are balanced by a similar rate of their consumption antioxidants (Sies, 1986) . Imbalance in the pro-oxidant antioxidant equilibrium in favour of pro-oxidants constitutes the oxidative stress phenomenon, a condition that may induce a number of pathophysiological events in the liver (Sies, 1986; Kaplowitz, 2000; Videla etal., 1995) . Hepatotoxicity by oxidative stress may be achieved through a direct attack of ROS and RNS on essential biomolecules with loss of their biological functions and cell viability (Sies, 1986; Kaplowitz, 2000; Videla et at, 1995) .
Alternatively, ROS may indirectly activate redox sensitive transcription factors such as nuclear factor IS (NF-M3) (Baeuerle and Henkel, 1994) or activator protein-1 (AP-1) (Karin etal., 1997) , thus triggering the production of cytotoxic, proinflammatory and/or fibrogenic mediators by Kupffer cells and other nonparenchymal cells (Tilg and Diehl, 2000) . These studies suggest that chronic oxidative stress may be important in the progression of NAFLD. Pessayre et al. (2001) have shown that excess fat deposition in the liver is associated with lipid peroxidation and the degree of this peroxidation is directly related to the severity of steatosis. The end-products of lipid peroxidation, 4-hydroxynoneal and malondialdehyde, covalently bind to hepatic proteins, and act as potent agents for neutrophil chemotaxis and stimulating pro-inflammatory cytokines. Malondialdehyde also activates hepatic stellate cells to produce collagen, leading to fibrosis.
Mitochondrial damage and NASH
Mitochondrial dysfunction seems to be a critical event in the second hit of NASH. Whether induced by lipid peroxidation products secondary to oxidative stress or directly by TNF-a, it leads to alterations in electron transfer along the respiratory chain, thus generating more free oxygen radicals (Pessayre et at, 2002) .
There are other potential sources of oxidative stress, including the cytochrome P450 enzymes CYP2E1
and CYP3A4 (Leclercq et a!., 2000) and increased hepatic iron content (George et at, 1998) .The expression of mitochondrial oxidative phosphorylation uncoupling protein 2 is increased. This protein reduces free oxygen radical synthesis, but it also decreases ATP levels, thus making the cell more sensitive to insults Chavin et al, 1999; Echtay et a!., 2002) and facilitating hepatocellular apoptosis and necrosis.
Patients with NASH due to the obesity/hypertriglyceridemia/insulin resistance syndrome exhibit ultrastructural mitochondrial lesions (with the presence of linear crystalline inclusions in megamitochondria) (Sanyal et al, 2001) . Activity of respiratory chain complexes is decreased (PerezCarrera et al., 1999) ; hepatic ATP levels tend to be low, and these patients slowly resynthesize ATP in vivo after a fructose challenge that causes acute hepatic ATP depletion . Finally, they may develop oxidative stress-mediated deletions of mitochondrial DNA (a genome that is located in the mitochondrial matrix and encodes some of the polypeptides of the mitochondrial respiratory chain) (Bohan et al., 2000) .
Cytokine and NASH
Recently a connection between Kupffer cells and the progression of non alcoholic steatosis to steatohepatitis and fibrosis was reported (Malaguarnera et al., 2006) . A significant correlation was Figure 5 . Potential rational targets for biomarkers development in NASH based on the pathophysiologyof the disease. Hepatocyte steatosis is a prerequisite for the subsequent events that lead to liver injury and fibrogenesis. Mitochondrial dysfunction is thought to play a central role in the progression from steatosis to NASH to cirrhosis. Different mechanisms have been proposed including (1) an increased production of reactive oxygen species, and mitochondrial outer membrane permeabilization, resulting in a cascade of events leading to (2) inflammation, (3) hepatocellular apoptosis, and (4) fibrogenesis and fibrosis. ROS, reactive oxygene species; TNF-a, tumor necrosis factor-a; CRP, C-reactive protein; CCL2, CCchemokineligand-2; FasL, Fas ligand; RBP-4, retinol binding protein-4; HSC, activated stellate cell; TGF-_, tumor growth factor-_; HA, hyaluronic acid; ECM, extracellular matrix; CK-18, cytokeratin-18. Question marks are placed on potential biomarkers in which no data is currently available.
Bone metabolism disorder and NASH
After cancer, cirrhosis from NASH is now the second most common age-related cause of death in type2
diabetes. Similar alarming observation is the association between human bone diseases in patients with liver diseases, like viral liver cirrhosis is a risk factor for increased loss of minerals from bone (Gonzalez- In an identical manner, patients with cholestatic liver disease have low bone turnover (Weinreb et al., 2004) . Even earlier van Daele et al., 2000) it was reported that hepatic diseases are frequently associated with metabolic bone disorders. Hepatic osteodystrophy was reported to occur in up to 50% of patients with chronic liver disease (CLD) (Crosbie et at, 1999) . The results of this report suggested that increased bone resorption and less bone formation are the predominant cause of hepatic osteodystrophy in patients with CLD and therapeutic strategies should be designated to suppress bone resorption. Earlier, in an attempt to measure the bone mineral density (BMD) in women with primary biliary cirrhosis and to evaluate whether BMD was related to liver disease, hormonal status and corticosteroid use, Le Gras et at (2002) observed that primary biliary cirrhosis-associated bone loss was significantly related to postmenopausal estrogen deficiency which could be effectively prevented by hormone replacement therapy (HRT). Interestingly, the severity of primary biliary cirrhosis was not a determinant factor for bone loss in these women. Earlier study also showed that diets with a high saturated fat can produce deleterious effects on the absorption of dietary calcium and consequently an adverse effect on bone mineralization in growing animals (Wohi etal, 1998) .
In contrast to the previous study, Sokhi et al. (2004) who determined the BMD in different subgroups among pre-transplant cirrhotic patients observed that there were significant difference in BMD values between males and females, and in addition, there was no significant influence of menopausal status, hormone replacement therapy, and etiology of cirrhosis on BMD. This observation has been further supported by Ormarsdottir et al. (2004) who have reported that transdermal HRT increases bone loss in primary biliary cirrhosis (PBC) patients with few severe side effects related to liver.
Therapeutic alternatives of NASH
At present, there is no widely accepted approach to treat NASH. The various therapeutic alternatives, as follows, are aimed at interfering with the risk factors considered to be involved in the etiology of NASH.
Change in habits
Diet and physical exercise significantly reduce the risk of developing type-2 diabetes (Chamberlain et a/., 2001) . Given the important relationship between insulin resistance and NAFLD, a change in habits is advisable. Reducing weight can improve hepatic enzyme alterations and histology in patients with NASH Erikkson et al., 1986) . Dietary restriction and physical exercise led to improved liver enzymes in obese patients who lost weight versus patients whose weight remained unchanged or increased, and serial biopsies also showed a significant improvement in hepatic steatosis (Agrawal and Bonkoysky, 2002).
Lipid-lowering drugs
A randomized trial on gemfibrozil (Basaranoglu et al., 1999) 600 mg daily for four weeks showed a significant improvement of transaminases, which did occur in the control group. The administration of clofibrate 2 mg daily for one year showed no changes in analytical findings, steatosis, inflammation, or fibrosis (Laurin et al., 1996) . In two patients with breast cancer who received bezafibrate for tamoxifeninduced NASH, subsequent computer tomographic assessments could not detect hepatic steatosis (Salbara et al., 1999) . By acting as a ligand of the proliferating-activated peroxysomal a receptor, this drug could compensate for the insufficient mitochondrial oxidation in patients with NASH. Treatment with probucol, a lipid-lowering drug with potent antioxidant properties, at a dose of 500 mg/day for 6 months, achieved a significant reduction in transaminase levels in 27 patients with NASH (Merat et al., 2003) . The preliminary results of treatment with atorvastatin are promising and indicate that 3-hydroxy3methylgIutaryl-coenzyme A reductase inhibitors may be useful in the treatment of NASH (Harlander et al., 2001) .
Drugs that improve insulin sensitivity
In 
Ursodeoxycolicacid
In three pilot studies (Laurin ef a/., 1996; Guma ef a/., 1997; Ceriani ef al, 1998) this hydrophilic bile acid with membrane-stabilizing, cytoprotective, and immunomodulating properties was found to improve or normalize liver function. However, in another randomized study that included 166 patients with histologically demonstrated NASH under treatment with 13-15 mg/kg/day of ursodesoxycolic acid or placebo for two years no significant changes were found in the degree of steatosis, necroinflammation or fibrosis between both groups at the end of the study (Lindor ef al., 2004) . Further controlled and randomized trials in larger numbers of patients are warranted, perhaps using higher doses (15-20 mg/kg/day) and for longer periods.
Antioxidants
Oral vitamin E 400-1200 IU daily improves hepatic enzymes in patients with, and also in certain animal models of, NAFLD (Nanji et al, 1996; Lavine, 2000) . It might improve NASH by modulating cytokines (Haseagawa et al, 1997) , and inhibiting the expression of intrahepatic TGF-^1, which is involved in fibrogenesis. Because it is well tolerated and low-cost, its use in the treatment of this condition is appealing. Betaine is a choline metabolite that increases S-adenosylmethionine levels, protects the liver from triglyceride deposits and oxidative stress in mice fed with alcohol, and may therefore have some efficacy as an antioxidant in NAFLD (Barak et al, 1997) . In a pilot study carried out in 10 patients with NASH (Abdelmalek et al, 2001) , betaine reduced hypertransaminasemia and achieved histological improvement of steatosis and necroinflammation.
Silimarine is derived from herbs commonly used in the treatment of hepatic diseases, and also has antioxidant properties. It stimulates ribosomal polymerase RNA, is an iron chelator, and reduces tumor promotion activity. Velussi (Veiussi et al, 1997) evaluated the efficacy of silimarine in reducing lipid peroxidation and insuDn resistance in diabetics with alcoholic cirrhosis. At 12 months, baseline glucose levels, insulin levels, and maiondialdehyde levels decreased.
N-acetylcysteine increases hepatic gluthatione levels and protects the liver from oxidative stress. Eleven patients with histologically demonstrated NASH who were treated with N-acetylcysteine 1000 mg/day for 3 months showed a significant decrease in transaminase and gamma-glutamyltranspeptidase levels; one patient was withdrawn from the study due to epigastralgia (Gulbahar et al, 2000) .
Antibiotics
In rats receiving total parenteral nutrition the administration of polymixin B and metronidazole reduced the degree of hepatic steatosis and TNF-a production, most of which comes from Kuppfer cells that might have been activated by endotoxins (Pappo et al., 1991; Freund et a/., 1985) .
Nutritional supplementation
Carnitine and/or choline deficiency may contribute to the appearance of steatosis or NASH by reducing free fatty acid oxidation and VLDL secretion. In a group of patients receiving prolonged total parenteral nutrition, intravenous choline supplementation returned plasma choline levels to normal, and steatosis completely disappeared, which was confirmed by CT (Buchman et al., 1995) .
Therapeutic phlebotomies
They are another option that should be considered for patients with NASH and iron overload, as mentioned earlier (Desai, 2000; Nitecki, 2000) . Iron depletion has been beneficial regarding coronary response, endothelial dysfunction, insulin secretion, insulin action, and metabolic control of type-2 diabetes (Fernandez-Real et al., 2002) . Guillygomarc'h et al. (2001) pointed out that performing a phlebotomy in patients with hepatic iron overload associated with insulin resistance not only achieved a subjective improvement without adverse effects, but can also reduce the risk of hepatic fibrosis, cancer, and cardiovascular disease. Facchini et al. (2002) observed that phlebotomy performed in carbohydrateintolerant patients and NAFLD patients improved plasma insulin levels during fasting and after glucose stimulation, and transaminase returned to nearly normal levels, which shows the insulin-saving effect of iron depletion and the important role of iron and hyperinsulinemia in the pathogenesis of NAFLD.
Liver Transplantation
Liver transplantation should be considered whenever complications appear. It has been estimated that about 3% of liver transplantations in the US are performed for NASH-induced end-stage liver disease . Recurrence of NASH within one year after transplantation may occur in one-third of patients (Contos etal., 2001; Charlton ef al., 2001 ).
TEA -A Possible new therapeutic alternative of NASH
Tea has been consumed socially and habitually by people tor so long (since ± 3000 BC), that aside from the astringent taste and boost it provides, it's medicinal properties are often over-looked. However, traditional healers have long believed that drinking tea is a means of prolonging life (Chopra and David, 2000) . After water, tea is the most popularly consumed beverage worldwide with a per capita consumption of 120ml/ day. It is the brew prepared from the leaves of the plant Camellia sinensis.
Camellia sinensis is native to mainland South and Southeast Asia, but is today cultivated across the world, in tropical and subtropical regions. It is an evergreen shrub or small tree that is usually trimmed to below two metres (six feet) when cultivated for its leaves (http://en.wikipedia.org/wiki/Camellia_sinensis).
Freshly harvested tea leaves require processing to convert them into green, oolong and black tea.
Types of Tea and its Constituents
There are three main types of tea Black tea, Green tea and Oolong tea. Black tea is consumed principally in Europe, North America and North Africa (except Morocco) while green tea is drunk throughout Asia; oolong tea is popular in China and Taiwan. All tea is produced from the leaves of the tropical evergreen Camellia sinensis. Approximately 76% to 78% of the tea produced and consumed worldwide is black, 20% and 22% is green and less than 2% is oolong (McKay and Blumberg, 2002) .
Green tea is produced by steaming or pan-frying fresh tea leaves, which inactivates the enzymes and prevents the oxidation of tea constituents. A typical brewed green tea (2 g of tea leaves in 200 mL of hot water) contains 500-700 mg of water extractable materials, of which 30-40% (by dry weight) are catechins. (-)-Epigallocatechin-3-gallate (EGCG), (-)-epigallocatechin, (-)-epicatechin-3-gallate, and (-)-epicatechin are the major tea catechins (Yang et al., 2008) . Black tea is made via a post-harvest "fermentation," an auto-oxidation catalyzed by polyphenol oxidase, in which the tea leaves are crushed to promote enzymatic oxidation and subsequent condensation of tea catechins, leading to the formation of oligomeric polyphenols (theafiavins) and polymeric polyphenols (thearubigins.) Black tea contains 2-6% theafiavins, >20% thearubigins, and 3-10% catechins in the water-extractable material (Yang etal., 2008) .
In manufacturing black tea, the tea leaves are crushed to allow the polyphenol oxidase to catalyze the oxidation, leading to polymerization of catechins. When tea leaves are rolled or broken during industry manufacture, catechins come in contact with polyphenol oxidase, resulting in their oxidation and the formation of flavanol dimers and polymers known as theafiavinsanti thearubigins, respectively. Theaflavins, which include theaflavin, theafiavin-3-gallate, iheafIavin-3'-gallate and theaflavin-3,3'-digallate, are key to the characteristic color and taste of black tea, and account for 2-6% of the solids in brewed black tea. The major fractions of black tea polyphenols, accounting for >20% of the solids in brewed black tea, are known as thearubigens. They have larger molecular weights and are poorly characterized chemically (Yang and Landau, 2000) .
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Oolong tea is produced by partial fermentation and contains less catechins but more theaflavins and other polymerized catechin derivatives than green tea. Tea leaves also contain flavonols, such as quercetin and myricitin, as well as nitrogenous compounds, such as caffeine and theobromine. Caffeine accounts for 2-5% of the water-extractable material in green, oolong, and black teas (Yang etal, 2008) .
Flavonoid content of black tea and green tea
Tea is a rich source of polyphenolics, particularly flavonoids. Flavonoids are phenol derivatives synthesized in substantial amounts (0.5%-1.5%) and variety (more than 4000 identified), and widely distributed among plants (McKay DL and Blumberg JB. 2002) . Black and green teas both contain similar amounts of flavonoids however they differ in their chemical structure. Green teas contain more of the simple flavonoids called catechins, while the oxidation that the leaves undergo to make black tea converts these simple flavonoids to the more complex varieties called theaflavins thearubigins. Table 2 provides average values for the different flavonoids present in green and black tea. Oolong tea is a partially fermented leaf, with a flavonoid profile midway between green and black tea. The flavonoid concentration of any particular tea beverage depends upon the type of tea (e.g., blended, decaffeinated instant) and preparation (e.g., amount used, brew time, temperature) (http://en.wikipedia.org/wiki/Camellia_sinensis). The highest concentration of flavonoids are found in brewed hot tea (541-692 pg/ml) (Hakim etal., 2000) , less in instant preparation (90-100 pg/ml) and lower amounts in iced and ready-to-drink tea (Arts et al., 2000) . The addition of milk or water (e.g., to iced tea)
can reduce the flavonoid concentration per saving, but research results are largely consistent in demonstrating that the addition of milk to tea does not interfere with catechin absorption (Leenen et al, 2000; van het Hof et al., 1998; Hollman et al., 2001) . Milk may affect the antioxidant potential of tea, depending upon its fat content and the volume added (Leenen et at, 2000; Serafini etal., 1996; Tewari etal., 2000; . (Miller, 1996) . There is enough epidemiological, clinical, and laboratory research on flavonoids, and to warrant their use in the prevention and/or treatment of cardiovascular disease, cancer, inflammatory conditions, asthma, periodontal disease, liver disease, cataracts and macular degeneration (Miller, 1996) . Although the antioxidant process modifies the types of flavonoids present, the total level and their overall antioxidant activity, is similar in both teas. Research is now suggesting that antioxidants, such as those found in both green and black tea, may have a protective role to play in certain conditions such as heart disease, stroke and some cancers (http://www.happyherbalist.com/blackteaextract.aspx).
The health benefits of flavonoids
Black tea and health benefits
People have been brewing tea made from the leaves of the Camellia sinensis plant for almost 50 centuries. Although health benefits have been attributed to tea consumption since the beginning of its history, scientific investigations of this beverage and its constituents has been underway for less than three decades.
Tea (Camellia sinensis tea is the most consumed beverage in the world (Katiyar et a/., 1996) . It is rich in polyphenolic compounds, collectively known as the tea flavonoids. Its therapeutic value come forefront with numerous reports on tea as antioxidants (Khan, 2006; Krishnamoorthy, 1991) , hypoglycaemic (Mukherjee et at., 1999; Vinson and Zhang, 2005) , hypolipidemic (Dufrense and Farnworth, 2001), antineoplastic (Frei and Higdon, 2003) and hypocholesteroiemic (Nag Chaudhuri et al., 2005) . Tea has also been reported to express a cardiovascular-protective effect (Imai et at, 1995; Vinson and Dabbagh 1998) . Tea flavonoids have been found, in vitro, to inhibit hepatic cytochrome P450 -dependent enzymes . Green tea extract is known to increase fat oxidation and 24-hour energy expenditure in humans experimentally. Furthermore, the fact that oolong tea extract may enhance nor-adrenaline-induced lipolysis in adipose tissue and inhibit pancreatic lipase activity seemed to suggest the possible anti-obesity action of tea consumption (Wu et al., 2003) . Tea and its constituents have been demonstrated to inhibit tumorigenesis in different organ sites including the lung, oral cavity, esophagus, stomach, small intestine, colon, skin, prostate, mammary glands, liver, pancreas, and bladder (Yang et al, 2008) Black tea, the major form of tea consumed in Western countries has been found more efficient than green tea and is an excellent chemopreventor against reactive oxygen and nitrogen species (Sarkar & Bhaduri, 2001 ). It has also been reported that the inclusion of black tea in the diet has the potential to significantly reduce blood cholesterol and thereby reduce the risk of chronic liver diseases (CLD) (Davies et al, 2003) . Earlier it was reported that black tea can be used therapeutically in diabetic patients as a substitute for oral hypoglycaemic agents (Mukherjee et al, 1999) . Very recently it has been reported that Japanese eating habits combined with drinking green tea might be a factor in preventing the onset of non insulin-dependent diabetes mellitus. (Shirai & Suzuki, 2004) and it also ameliorates insulin resistance with the increased expression of GLUT IV (Wu et al, 2004) . Tea flavonoids have been found, in vitro, to enhance gap junction communication, stimulate B cell proliferation and inhibit hepatic cytochrome P45Q-dependent enzymes . Recently, several clinical trials have demonstrated that a single dose of tea improves plasma antioxidant capacity of healthy adults within 30 to 60 minutes after ingestion.
Oxidative DNA damage, lipid peroxidation and free radical generation were reduced after consuming ~6 cups a day of green tea for seven days (Klaunig et al, 1999) . Similarly, ten patients with Type 2 diabetes consuming a high flavonoid diet for two weeks, including six cups a day of black tea, had a significant reduction {P=0.037} in oxidative damage to lymphocyte DNA (Lean et al., 1999) . Plasma malondialdehyde, another indicator of lipid peroxidation, was reduced (P < 0.05) in 20 healthy women, 23
to 50 years of age, consuming a high linoleic acid diet and administered an encapsulated tea extract (equivalent to 10 cups a day of green tea) for four weeks; however, no changes were noted relative to the placebo in urinary 8-isoprostaglandin Fza and blood oxidized glutathione (Freese et al., 1999) . These latter results may be confounded by the consumption of up to 560 mL/day of black tea by some subjects in both the control and treatment groups. Recent human studies suggest tea may contribute to a reduction in the risk of cardiovascular disease and some forms of cancer as well as to the promotion of oral health and other physiological functions (McKay & Blumberg, 2002) .). Reports further indicate that antitumor dose of black tea is capable of modulating the host's antioxidant system and regress cancer-induced ROS significantly, thereby protecting the host's liver from lipid peroxidation and subsequent degeneration (Bhattacharya et al., 2007) . More recently, the role of green and black tea polyphenols in the regulation of cancer cell growth and transformation, apoptosis, angiogenesis and metastasis through the regulation of multiple signaling pathways also have been reported (Archivio et al., 2008) .
In an epidemiological report it has been suggested that skeletal health is better preserved in aged women who drank tea than non-tea drinkers Wu et al., 2002; Chen et al., 2003) . Some epidemiological studies have confirmed tea drinking as a possible preventive measure to reduce risk of bone loss in postmenopausal women as well as in men by increasing BMD Wu ef al., 2002; Chen et al., 2003) . Nutrient found in tea, such as flavonoids, may influence BMD . Chronic Green Tea Consumption Decreases Body Mass Induces Aromatase Expression, and Changes Proliferation and Apoptosis in Adult Male Rat Adipose Tissue (Monteiro et al., 2008) . Tea is a major dietary source of flavonoids and lignans, some of which have estrogen-like activities. Synthetic phytoestrogens have been shown to benefit bone density, but via a different mechanism than estrogen (Devine et al., 2007) . A recent review suggests that flavonoids from green tea may be associated with increases in BMD (Cabrera et al., 2006) via a potent stimulatory effect on osteoblast function. A major tea flavonoid, (-)-epigallocatechin-3-gallate, has been shown to increase the expressions of osteogenic genes, elevate bone marker activity, and augment mineralization in a murine bone marrow mesenchymal stem cell line (Chen et al, 2005) . Black tea extract has also been shown to reduce the risk of bone loss in hypogonadal condition (Das et al., 2004; Das et al, 2005; Das et al., 2009) . Estrogenic activity of naturally occurring isoflavones by virtue of their ability to bind nuclear estrogen receptor was reported earlier (Miksicek, 1993) and recently soy isoflavones with weak estrogen like activities has been shown to modulate bone metabolism and serum lipids in perimenopausal women (Uesugi et al, 2002) . A recent study also reports that soy isoflavone can reduce the risk of obesity and also preserve bone health in menopausal women (Mori et al, 2004) .
In view of accumulating evidence of beneficial effects of tea, we propose to examine whether black tea extract/infusion, which is rich with polyphenol esters (theaflavine gallate and digallate) and complex polyphenols (thearubigens) has any preventive or protective efficacy against NASH-mediated hepatic and bone damages.
Plan of Work
An animal model of NASH was developed with high-lipid diet supplementation (Baumgardner et al, 2005) . Then the whole study was planned in the following two phases and each phase has been described in the subsequent two chapters.
*' Phase-Î
Phase-II
Studies to examine the Nonalcoholic steatohepatitis-induced alteration of hepatic functions and its amelioration by supplementation with BTE -its mechanism of action; (Chapter-II)
Studies to examine the Nonalcoholic steatohepatitis-induced skeletal dysfunction and its amelioration by supplementation with BTE-its mechanism of action; (Chapter -III)
